William Hahn, M.D., Ph.D.
William Hahn is an institute member of the Broad Institute’s Cancer Program. He is a medical oncologist and the William Rosenberg Professor of Medicine at the Dana–Farber Cancer Institute and Harvard Medical School. At Dana-Farber, he also serves as chief scientific officer and chair of the Executive Committee for Research.
Hahn’s work as a physician-scientist involves both the care of cancer patients and biomedical research directed toward a greater understanding of the mechanisms involved in malignant transformation. At the Broad, he leads efforts to apply functional genomic approaches to cancer. He is a founding member of The RNAi Consortium (TRC) and the DepMap Consortium, Broad Institute-based efforts that have developed tools for somatic cell genetics in mammalian cells. Hahn’s own lab is engaged in using RNAi, CRISPR and ORF libraries to identify cancer vulnerabilities.
Hahn has been the recipient of several honors and awards, including the Wilson S. Stone Award from MD Anderson Cancer Center for outstanding research in cancer, the Howard Temin Award from the National Cancer Institute, the Gill-Siminion Prize for Mentoring, the Richard and Hinde Rosenthal Award from the AACR, and the Claire and Richard Morse Award from DFCI. Hahn is also a Ho-Am Laureate in Medicine and was elected to the American Society of Clinical Investigation in 2005 and the Association of American Physicians in 2013.
Hahn holds a B.A. from Harvard University, and an M.D. and Ph.D. from Harvard Medical School. He completed clinical training in internal medicine at Massachusetts General Hospital and medical oncology at Dana-Farber. He conducted his postdoctoral studies in the lab of Robert Weinberg at the Whitehead Institute for Biomedical Research.